Israel’s NeoTX Therapeutics (see here Mar 2020) has had FDA approval to begin Phase 2a human trials of its Naptumomab Estafenatox (NAP) treatment for non-small cell lung cancer. NAP binds bacteria to the tumor while activating tumor specific immune cells.

https://neotx.com/neotx-announces-fda-clearance-of-ind-for-phase-2-clinical-trial-of-naptumomab-estafenatox-nap-its-lead-tumor-targeted-superantigen-candidate/